Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04970498
Other study ID # M2021111
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2021
Est. completion date October 31, 2022

Study information

Verified date July 2021
Source Peking University Third Hospital
Contact ? ?, Professor
Phone 13501241339
Email 13501241339@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rectal cancer patients who received neoadjuvant chemoradiotherapy in Peking University Third Hospital in 2021 are divided into acute myelosuppression group, chronic myelosuppression group and normal group. The differences of magnetic resonance parameters between the groups were compared. The risk identification model of acute and chronic myelosuppression after neoadjuvant chemoradiotherapy was established by clinical risk factors and quantitative parameters of magnetic resonance imaging, and the prediction efficiency of the model was evaluated.


Description:

The patients with locally advanced rectal cancer diagnosed in Peking University Third Hospital and undergoing neoadjuvant chemoradiotherapy were collected. The basic information of patients (including age, sex, BMI, TNM stage of rectal cancer (T2, T3 stage)) was collected. The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy. MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed, and the corresponding parameters were obtained. The white blood cell values and quantitative parameters of magnetic resonance (including T1WI, DWI signal intensity (b = 1000) and proton density fat fraction (PDFF) of sacrilium and proximal femur were collected. Patients were divided into acute myelosuppression group and non-acute myelosuppression group according to blood routine results 14 days after radiotherapy, and chronic myelosuppression group and non-chronic myelosuppression group according to blood routine results 90 days after radiotherapy. The magnetic resonance parameters difference between 1-2 weeks after radiotherapy and before radiotherapy, and the magnetic resonance parameters difference between 90 days after radiotherapy and before radiotherapy were calculated. By comparing the differences of clinical risk factors and quantitative parameters of MRI between the two groups, the meaningful variables were screened out, and the risk identification model of acute and chronic myelosuppression was established.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date October 31, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - From February 2021 to August 2022, patients with locally advanced rectal cancer were treated with neoadjuvant chemoradiotherapy in the Third Hospital of Peking University. - There were blood routine before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy, and MRI examination including routine MRI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks and 90 days after radiotherapy. - Each patient used the same chemotherapy regimen. Exclusion Criteria: - Patients with metabolic bone diseases such as hyperparathyroidism and Cushing's syndrome. - Patients with history of pelvic radiotherapy or systemic chemotherapy. - Patients with leukocytes below 4.0×10^9/L or long-term severe anemia before radiotherapy. - Patients with tumor bone metastases; patients with pelvic trauma, fracture, and infectious diseases.

Study Design


Intervention

Diagnostic Test:
MRI
MRI including T1WI, DWI sequence and IDEAL-IQ sequence before radiotherapy, 1-2 weeks after radiotherapy and 90 days after radiotherapy were performed
blood routine test
The blood routine was collected before radiotherapy, 1 week, 2 weeks and 90 days after radiotherapy.

Locations

Country Name City State
China Peking University third hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes of IDEAL-IQ sequence of MRI The differences of PDFF(%) between the acute myelosuppression group and no suppression group 1-2 weeks after radiotherapy
Primary Changes of T1WI sequence of MRI The differences of T1WI signal intensity(IU) between the acute myelosuppression group and no suppression group 1-2 weeks after radiotherapy
Primary Changes of DWI sequence of MRI The differences of DWI signal intensity(IU)between the acute myelosuppression group and no suppression group 1-2 weeks after radiotherapy
Primary Changes of ADC map of MRI The differences of ADC value(mm^2/s) between the acute myelosuppression group and no suppression group 1-2 weeks after radiotherapy
Primary Changes of IDEAL-IQ sequence of MRI The differences of PDFF(%) between the chronic myelosuppression group and no suppression group 90 days after radiotherapy
Primary Changes of T1WI sequence of MRI The differences T1WI signal intensity(IU)between the chronic myelosuppression group and no suppression group 90 days after radiotherapy
Primary Changes of DWI sequence of MRI The differences of DWI signal intensity(IU)between the chronic myelosuppression group and no suppression group 90 days after radiotherapy
Primary Changes of ADC map of MRI The differences of ADC value(mm^2/s) between the chronic myelosuppression group and no suppression group 90 days after radiotherapy
See also
  Status Clinical Trial Phase
Completed NCT05495308 - "Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Recruiting NCT04598984 - The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
Active, not recruiting NCT04246684 - Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients Phase 3
Completed NCT05723965 - Using Artificial Intelligence to Predict Rectal Cancer Outcomes
Not yet recruiting NCT05830890 - Sentinel Lymph Node Biopsy in Rectal Cancer N/A
Active, not recruiting NCT04503694 - Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer Phase 2
Completed NCT02363374 - Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT03561142 - Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. Phase 2
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2
Recruiting NCT05148767 - UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer Phase 4
Recruiting NCT06254521 - The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer Phase 2
Completed NCT01325649 - Optimal Surgery and MRI Based Radiochemotherapy in Rectal Carcinoma N/A
Active, not recruiting NCT03840239 - TNT to Increase the Clinical Complete Response Rate for Distal LARC Phase 2
Active, not recruiting NCT03391843 - Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer Phase 2